

AMENDMENTS TO THE CLAIMS

Please amend claims 1-6 as follows:

1. (Currently Amended) An agent for treatment of pemphigoid, containing comprising interferon- γ as an active ingredient.
2. (Currently Amended) The agent for treatment according to claim 1, which is administered in a form suitable for administration in a daily dose of 200,000 to 4,000,000 JRU-, preferably 2,000,000 JRU.
3. (Currently Amended) The agent for treatment according to claim 1 or 2, which is in a form suitable pharmaceutical preparation for intravenous injection.
4. (Currently Amended) The agent for treatment according to claim 1, further comprising any one of claims 1 to 3, which is used in combination with an antihistaminic, an antiallergic and/or a corticosteroid.
5. (Currently Amended) The agent for treatment according to any one of claims 1 to 4, wherein pemphigoid is bullous pemphigoid, cicatricial pemphigoid, or nodular pemphigoid.
6. (Currently Amended) The agent for treatment according to any one of claims 1 to 4, wherein pemphigoid is bullous pemphigoid.
7. (New) The agent for treatment according to claim 2, wherein said daily dose is, 2,000,000 JRU.
8. (New) The agent for treatment according to claim 1, wherein said interferon- γ is an interferon- γ mutant.
9. (New) A therapeutic composition comprising interferon- γ as an active ingredient and a pharmaceutically acceptable carrier, said interferon- γ being present in an amount effective to treat pemphigoid.

10. (New) A method for treating pemphigoid comprising administering to a patient the therapeutic composition of claim 9.

11. (New) The method according to claim 10 comprising administering said composition intravenously.